NASDAQ:TTPHTetraphase Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tetraphase Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.63 +0.19 (+7.79 %) (As of 07/7/2020 12:44 PM ET) Add Compare Share Today's Range$2.40Now: $2.63▼$2.6350-Day Range$2.16MA: $2.43▼$2.7752-Week Range$0.56Now: $2.63▼$10.52Volume3,885 shsAverage Volume445,149 shsMarket Capitalization$19.09 millionP/E RatioN/ADividend YieldN/ABeta2.33 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.Read More Beat the Market (BTM) Rank™ 2.9 Analyst's Opinion Consensus RatingTetraphase Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.00, Tetraphase Pharmaceuticals has a potential upside of 1,420.9% from its current price of $2.63.Amount of Analyst CoverageTetraphase Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesTetraphase Pharmaceuticals has received 383 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTetraphase Pharmaceuticals has received 375 “underperform” votes. (Add your “underperform” vote.)Community SentimentTetraphase Pharmaceuticals has received 50.53% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote “Outperform” if you believe TTPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TTPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTetraphase Pharmaceuticals does not currently pay a dividend.Dividend GrowthTetraphase Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tetraphase Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $614,909.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.70% of the stock of Tetraphase Pharmaceuticals is held by insiders.Percentage Held by Institutions42.29% of the stock of Tetraphase Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Tetraphase Pharmaceuticals are expected to grow in the coming year, from ($3.95) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tetraphase Pharmaceuticals is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tetraphase Pharmaceuticals is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTetraphase Pharmaceuticals has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.9Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.13 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TTPH Previous Symbol CUSIPN/A CIK1373707 Webwww.tphase.com Phone617-715-3600Debt Debt-to-Equity Ratio0.06 Current Ratio3.66 Quick Ratio3.56Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$7.38 million Price / Sales2.59 Cash FlowN/A Price / Cash FlowN/A Book Value$6.68 per share Price / Book0.39Profitability EPS (Most Recent Fiscal Year)($22.85) Net Income$-70,080,000.00 Net Margins-798.18% Return on Equity-210.86% Return on Assets-121.73%Miscellaneous Employees119 Outstanding Shares7,260,000Market Cap$19.09 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:TTPH Rates by TradingView Receive TTPH News and Ratings via Email Sign-up to receive the latest news and ratings for TTPH and its competitors with MarketBeat's FREE daily newsletter. Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions How has Tetraphase Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Tetraphase Pharmaceuticals' stock was trading at $1.57 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TTPH shares have increased by 67.5% and is now trading at $2.63. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Tetraphase Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tetraphase Pharmaceuticals in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Tetraphase Pharmaceuticals. When is Tetraphase Pharmaceuticals' next earnings date? Tetraphase Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tetraphase Pharmaceuticals. How were Tetraphase Pharmaceuticals' earnings last quarter? Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.63) by $0.32. The biopharmaceutical company earned $1.76 million during the quarter, compared to analysts' expectations of $2.45 million. Tetraphase Pharmaceuticals had a negative return on equity of 210.86% and a negative net margin of 798.18%. View Tetraphase Pharmaceuticals' earnings history. When did Tetraphase Pharmaceuticals' stock split? How did Tetraphase Pharmaceuticals' stock split work? Shares of Tetraphase Pharmaceuticals reverse split before market open on Friday, September 27th 2019. The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 26th 2019. An investor that had 100 shares of Tetraphase Pharmaceuticals stock prior to the reverse split would have 5 shares after the split. What price target have analysts set for TTPH? 4 analysts have issued 1 year target prices for Tetraphase Pharmaceuticals' shares. Their forecasts range from $40.00 to $40.00. On average, they anticipate Tetraphase Pharmaceuticals' share price to reach $40.00 in the next year. This suggests a possible upside of 1,420.9% from the stock's current price. View analysts' price targets for Tetraphase Pharmaceuticals. What are Wall Street analysts saying about Tetraphase Pharmaceuticals stock? Here are some recent quotes from research analysts about Tetraphase Pharmaceuticals stock: 1. According to Zacks Investment Research, "Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. " (6/6/2020) 2. HC Wainwright analysts commented, "We are reiterating our Hold rating on PCRX shares after the company reported 2Q19 Exparel sales which were in-line with consensus. Given 3Q tends to be a low Q/Q growth quarter due to seasonality, we think this sets up the need for a big 4Q19 Exparel sales number for the company to beat guidance and for shares to meaningfully outperform. Additionally, we would expect shares to be volatile around updates from competitors HRTX (Buy, $17.87) and DRRX (Adam Walsh, Hold, $1.43) which we expect in the coming months – with positive updates from one or both weighing on shares. Overall, we continue to remain on the sidelines as we think shares seem fairly valued at these levels and the potential for incoming competition in the next ~6-12 months poses a headwind, in our view. Key Points Exparel sales met 2Q19 expectations and FY19 Exparel sales guidance was reiterated." (8/11/2019) Has Tetraphase Pharmaceuticals been receiving favorable news coverage? Headlines about TTPH stock have trended negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tetraphase Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Tetraphase Pharmaceuticals. Are investors shorting Tetraphase Pharmaceuticals? Tetraphase Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 368,900 shares, an increase of 5.1% from the June 15th total of 351,100 shares. Based on an average daily volume of 1,850,000 shares, the short-interest ratio is currently 0.2 days. Currently, 5.7% of the shares of the stock are short sold. View Tetraphase Pharmaceuticals' Current Options Chain. Who are some of Tetraphase Pharmaceuticals' key competitors? Some companies that are related to Tetraphase Pharmaceuticals include Proteostasis Therapeutics (PTI), CannTrust (CNTTF), Assertio Therapeutics (ASRT), Elite Pharmaceuticals (ELTP), VERONA PHARMA P/S (VRNA), Synlogic (SYBX), Stealth BioTherapeutics (MITO), Capricor Therapeutics (CAPR), ASLAN PHARMACEU/ADR (ASLN), Aclaris Therapeutics (ACRS), Lipocine (LPCN), 9 Meters Biopharma (NMTR), Citius Pharmaceuticals (CTXR), Aridis Pharmaceuticals (ARDS) and CV Sciences (CVSI). View all competitors. What other stocks do shareholders of Tetraphase Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tetraphase Pharmaceuticals investors own include Aurinia Pharmaceuticals (AUPH), Alcoa (AA), General Electric (GE), Bank of America (BAC), Opko Health (OPK), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Rite Aid (RAD), Melinta Therapeutics (MLNT) and Exelixis (EXEL). Who are Tetraphase Pharmaceuticals' key executives? Tetraphase Pharmaceuticals' management team includes the following people: Mr. Guy MacDonald B.Sc., B.Sc, CEO, Pres & Director (Age 60)Mr. Christopher Watt, Principal Financial & Accounting Officer (Age 54)Dr. Jacques Dumas, Chief Scientific Officer (Age 53)Ms. Maria D. Stahl, Sr. VP & Gen. Counsel (Age 48)Mr. Larry G. Edwards, Chief Operating Officer (Age 47) What is Tetraphase Pharmaceuticals' stock symbol? Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH." How do I buy shares of Tetraphase Pharmaceuticals? Shares of TTPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Tetraphase Pharmaceuticals' stock price today? One share of TTPH stock can currently be purchased for approximately $2.63. How big of a company is Tetraphase Pharmaceuticals? Tetraphase Pharmaceuticals has a market capitalization of $19.09 million and generates $7.38 million in revenue each year. The biopharmaceutical company earns $-70,080,000.00 in net income (profit) each year or ($22.85) on an earnings per share basis. Tetraphase Pharmaceuticals employs 119 workers across the globe. What is Tetraphase Pharmaceuticals' official website? The official website for Tetraphase Pharmaceuticals is www.tphase.com. How can I contact Tetraphase Pharmaceuticals? Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL WAY, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected] This page was last updated on 7/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
